Akhtar Ashfaq, MD
OPKO Health · OPKO Health, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Akhtar Ashfaq, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:12 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05543928 · Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary HyperparathyroidismOPKO Health, Inc. · terminated · Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency · study director
- Ph2NCT04551911 · Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19OPKO Health, Inc. · completed · COVID-19, Coronavirus, SARS-CoV2 Infection · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.